Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics     Learn More
Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics     Learn More
Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
First study demonstrating Decipher Prostate test can inform treatment decisions in nmCRPC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data demonstrating the prognostic utility of the company’s Decipher ® Prostate genomic
View HTML
Toggle Summary Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
First Molecular Subtyping Test to Gain Medicare Coverage to Inform Treatment for Individuals With Bladder Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 4, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Medicare Administrative Contractors Palmetto GBA, WPS and CGS
View HTML

Events

Date Event Details
Summary Toggle Jun 23, 2021 2:40 PM EDT
Raymond James Human Health Innovation Conference

Presentations

Title Documents

Corporate Presentation June 2021